NASH and Metabolic Associated Fatty Liver Disease

The incidence of liver steatosis with or without hepatitis NAFLD, NASH) is increasing tremendously worldwide and is leading to increasing numbers of patients with hepatocellular carcinoma and liver cirrhosis. There is no effective treatment available yet, although progress is being made rapidly. The studies that are being conducted are currently taken place in the ERGO center Rotterdam, focusing on the epidemiology among an elderly population. Collaboration is with different other departments in the Erasmus MC but also with several clinical centers in the European Union. Currently there is participation within a large EU-funded multinational study in the European Union (www.liverscreen.eu and www.eithealth.eu/product-service/fisplat).

Recent publications

  • Van Kleef LA et al., Metabolic dysfunction-association fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Reports 2021

  • Van Kleef LA et al. Objectively measured physicial activity is inversely associated with nonalcoholic fatty liver disease: the Rotterdam Study. Am J Gastroenterol 2022

  • Ayada I et al. Systemically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2022